You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Understanding secondary AML treatment with VYXEOS

Find out why this advancement in chemotherapy may be an appropriate treatment choice for you or your loved one 1 year of age and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

People Icon

VYXEOS treatment journey

Learn more about dosing schedules, what to tell your doctor, and helpful tips during therapy.

Explore sAML treatment
Papers Icon

VYXEOS and sAML resource library

Download educational disease information and find support groups to connect with others in the AML community.

Get support for VYXEOS and sAML


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.